Zhejiang Ausun Pharmaceutical Co., Ltd. (AUSUN PHARM) was founded in April 2010 with the ambition to bring its mission - “Advancing health, shaping the future together” - into practice. Since May 9, 2017, AUSUN PHARM has been listed on the Shanghai Stock Exchange under the stock code 603229.
Located in the Taizhou Bay Economic and Technological Development Zone in Zhejiang Province, AUSUN PHARM is recognized as a national high‑tech enterprise. AUSUN PHARMis committed to enhancing the accessibility of healthcare in both domestic and international markets through the research, development, and manufacturing of pharmaceutical preparations, active pharmaceutical ingredients, and key intermediates. In addition, AUSUN PHARM provides customized contract development and manufacturing services tailored to the specific needs of its partners.
To serve customers effectively, Ausun Pharm has built a strategically positioned network of sales offices in key global markets. AUSUN PHARM’s portfolio continues to expand, supported by extensive, technology‑driven R&D capabilities that form the foundation of future product portfolio. AUSUN PHARM further strengthens its innovation capacity through a broad network of external experts, enabling AUSUN PHARM to push scientific boundaries and deliver long‑term value to customers and stakeholders.
Quality and sustainability are core priorities for every member of the organization. AUSUN PHARM maintains a strong record of successful quality, ESG, and HSE audits conducted by recognized national and international regulatory authorities as well as by its customers, reflecting AUSUN PHARM’s commitment to high standards and responsible operations.
No. 5, East Fourth Avenue, Linhai Park, Zhejiang Chemical API Base, Zhejiang Province
No. 21, East Eighth Avenue, Linhai Park, Zhejiang Chemical API Base, Zhejiang Province
